Disease biomarkers in multiple sclerosis: Potential for use in therapeutic decision making

Molecular Diagnosis and Therapy

Volumn 13, Issue 4, 2009, Pages 225-244

  Harris, Violaine K ^a   Sadiq, Saud A ^a  

^a Multiple Sclerosis Research Center of New York Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON RECEPTOR; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN; BETA INTERFERON; BETA1A INTERFERON; BIOLOGICAL MARKER; CXCL13 CHEMOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FETUIN A; GLATIRAMER; INTERFERON BETA SERINE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 6 RECEPTOR; MYELIN BASIC PROTEIN; MYXOVIRUS RESISTANCE PROTEIN A; N ACETYLASPARTIC ACID; NATALIZUMAB; NEUROFILAMENT PROTEIN; NEUTRALIZING ANTIBODY; NITRIC OXIDE SYNTHASE; OLIGOCLONAL BAND; OSTEOPONTIN; PROTEIN 14 3 3; PROTEIN NOGO A; STROMAL CELL DERIVED FACTOR 1; TAU PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNINDEXED DRUG;

ANTIBODY TITER; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITIVE DEFECT; CONCENTRATION (PARAMETERS); CYTOKINE PRODUCTION; DEMENTIA; DEMYELINATION; DIAGNOSTIC PROCEDURE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE MARKER; DRUG BIOAVAILABILITY; DRUG EFFICACY; ELECTROSPRAY MASS SPECTROMETRY; EPSTEIN BARR VIRUS; GENE EXPRESSION; GENETIC MARKER; GRAY MATTER; HIGH RISK POPULATION; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; LIQUID CHROMATOGRAPHY; MEDICAL DECISION MAKING; MICROARRAY ANALYSIS; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; REGENERATION; REMYELINIZATION; REVIEW; SENSITIVITY AND SPECIFICITY; SPINAL CORD DISEASE; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

BIOLOGICAL MARKERS; HUMANS; MULTIPLE SCLEROSIS;

EID: 69349092075     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.2165/11313470-000000000-00000     Document Type: Review

References (203)

1. Fox RJ, Bethoux F, Goldman MD, et al. Multiple sclerosis: advances in understanding, diagnosing, and treating the underlying disease. Cleve Clin J Med 2006; 73: 91-102
2. Gonen O, Moriarty DM, Li BS, et al. Relapsing-remitting multiple sclerosis and whole-brain N-acetylaspartate measurement: evidence for different clinical cohorts - initial observations. Radiology 2002 Oct; 225 (1): 261-268
3. Kantarci O, Wingerchuk D. Epidemiology and natural history of multiple sclerosis: new insights. Curr Opin Neurol 2006 Jun; 19 (3): 248-254 (Pubitemid 43804678)
4. Sadiq SA. Multiple sclerosis. In: Roland LP, editor. Merritt's neurology. 11th ed. Philadelphia (PA): Lippincott, Williams, and Wilkins, 2005: 941-963
5. Barkhof F. The clinico-radiological paradox in multiple sclerosis revisited. Curr Opin Neurol 2002 Jun; 15 (3): 239-245 (Pubitemid 34596884)
6. PRISMS (Prevention of Relapses and Disability by Interferon-beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998 Nov 7; 352 (9139): 1498-1504
7. Friese MA, Montalban X, Willcox N, et al. The value of animal models for drug development in multiple sclerosis. Brain 2006 Aug; 129 (Pt 8): 1940-1952 (Pubitemid 44289061)
8. Morrissey SP, Miller DH, Kendall BE, et al. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis: a 5-year follow-up study. Brain 1993 Feb; 116 (Pt 1): 135-146
9. Paolino E, Fainardi E, Ruppi P, et al. A prospective study on the predictive value of CSF oligoclonal bands and MRI in acute isolated neurological syndromes for subsequent progression to multiple sclerosis. J Neurol Neurosurg Psychiatry 1996 May; 60 (5): 572-575 (Pubitemid 26147901)
10. Perumal J, Zabad R, Caon C, et al. Acute transverse myelitis with normal brain MRI: long-term risk of MS. J Neurol 2008 Jan; 255 (1): 89-93
11. Compston A, Wekerle H. The genetics of multiple sclerosis. In: Compston A, editor. McAlpine's multiple sclerosis. Philadelphia (PA): Churchill Livingstone Elsevier, 2006: 113-181
12. Hafler DA, Compston A, Sawcer S, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007 Aug 30; 357 (9): 851-862 (Pubitemid 47347319)
13. Peltonen L. Old suspects found guilty: the first genome profile of multiple sclerosis. N Engl J Med 2007 Aug 30; 357 (9): 927-929 (Pubitemid 47347328)
14. Maier LM, Anderson DE, Severson CA, et al. Soluble IL-2RA levels in multiple sclerosis subjects and the effect of soluble IL-2RA on immune responses. J Immunol 2009 Feb 1; 182 (3): 1541-1547
15. Linington C, Bradl M, Lassmann H, et al. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol 1988 Mar; 130 (3): 443-454 (Pubitemid 18091372)
16. Schluesener HJ, Sobel RA, Linington C, et al.Amonoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease. J Immunol 1987 Dec 15; 139 (12): 4016-4021 (Pubitemid 18013691)
17. Kerlero de Rosbo N, Honegger P, Lassmann H, et al. Demyelination induced in aggregating brain cell cultures by a monoclonal antibody against myelin/oligodendrocyte glycoprotein. J Neurochem 1990 Aug; 55 (2): 583-587 (Pubitemid 20240056)
18. Genain CP, Cannella B, Hauser SL, et al. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 1999 Feb; 5 (2): 170-175 (Pubitemid 29068523)
19. Berger T, Rubner P, Schautzer F, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003 Jul 10; 349 (2): 139-145 (Pubitemid 36818783)
20. Kuhle J, Lindberg RL, Regeniter A, et al. Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF. J Neurol 2007 Feb; 254 (2): 160-168 (Pubitemid 46356047)
21. Kuhle J, Pohl C, Mehling M, et al. Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med 2007 Jan 25; 356 (4): 371-378 (Pubitemid 46148779)
22. Lim ET, Berger T, Reindl M, et al. Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis. Mult Scler 2005 Aug; 11 (4): 492-494 (Pubitemid 40984247)
23. Pelayo R, Tintore M, Montalban X, et al. Antimyelin antibodies with no progression to multiple sclerosis. N Engl J Med 2007 Jan 25; 356 (4): 426-428 (Pubitemid 46148809)
24. Rauer S, Euler B, Reindl M, et al. Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event. J Neurol Neurosurg Psychiatry 2006 Jun; 77 (6): 739-742 (Pubitemid 43837200)
25. Tomassini V, De Giglio L, Reindl M, et al. Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS. Mult Scler 2007 Nov; 13 (9): 1086-1094 (Pubitemid 351541411)
26. Pittock SJ, Reindl M, Achenbach S, et al. Myelin oligodendrocyte glycoprotein antibodies in pathologically proven multiple sclerosis: frequency, stability and clinicopathologic correlations. Mult Scler 2007 Jan; 13 (1): 7-16 (Pubitemid 46152756)
27. Belogurov Jr AA, Kurkova IN, Friboulet A, et al. Recognition and degradation of myelin basic protein peptides by serum autoantibodies: novel biomarker for multiple sclerosis. J Immunol 2008 Jan 15; 180 (2): 1258-1267
28. Lalive PH, Menge T, Delarasse C, et al. Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis. Proc Natl Acad Sci U S A 2006 Feb 14; 103 (7): 2280-2285 (Pubitemid 43271661)
29. Wang H, Munger KL, Reindl M, et al. Myelin oligodendrocyte glycoprotein antibodies and multiple sclerosis in healthy young adults. Neurology 2008 Oct 7; 71 (15): 1142-1146
30. Corvol JC, Pelletier D, Henry RG, et al. Abrogation of T cell quiescence characterizes patients at high risk for multiple sclerosis after the initial neurological event. Proc Natl Acad Sci U S A 2008 Aug 19; 105 (33): 11839-11844
31. Johnson D, Hafler DA, Fallis RJ, et al. Cell-mediated immunity to myelin-associated glycoprotein, proteolipid protein, and myelin basic protein in multiple sclerosis. J Neuroimmunol 1986 Nov; 13 (1): 99-108 (Pubitemid 16023787)
32. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis: part I. The role of infection. Ann Neurol 2007 Apr; 61 (4): 288-299
33. Donelan N, Dinzey J, Lin J, et al. Cerebrospinal fluid screening for evidence of Epstein Barr virus presence in multiple sclerosis [abstract no. P310]. Mult Scler 2008; 14 (1 Suppl.): S120
34. Jilek S, Schluep M, Meylan P, et al. Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis. Brain 2008 Jul; 131 (Pt 7): 1712-1721 (Pubitemid 351957461)
35. Riverol M, Sepulcre J, Fernandez-Diez B, et al. Antibodies against Epstein-Barr virus and herpesvirus type 6 are associated with the early phases of multiple sclerosis. J Neuroimmunol 2007 Dec; 192 (1-2): 184-185 (Pubitemid 350213113)
36. Virtanen JO, Farkkila M, Multanen J, et al. Evidence for human herpesvirus 6 variant A antibodies in multiple sclerosis: diagnostic and therapeutic implications. J Neurovirol 2007 Aug; 13 (4): 347-352 (Pubitemid 47400033)
37. Friedman JE, Zabriskie JB, Plank C, et al. A randomized clinical trial of valacyclovir in multiple sclerosis. Mult Scler 2005 Jun; 11 (3): 286-295 (Pubitemid 40775184)
38. Fossey SC, Vnencak-Jones CL, Olsen NJ, et al. Identification of molecular biomarkers for multiple sclerosis. J Mol Diagn 2007 Apr; 9 (2): 197-204 (Pubitemid 47305086)
39. Cohen SR, Brune MJ, Herndon RM, et al. Cerebrospinal fluid myelin basic protein and multiple sclerosis. Adv Exp Med Biol 1978; 100: 513-519
40. Wekerle H, Lassmann H. The immunology of inflammatory demyelinating disease. In: Compston A, editor. McAlpine's multiple sclerosis. 4th ed. Philadelphia (PA): Churchill Livingstone Elsevier, 2006: 491-555
41. Levin SD, Hoyle NR, Brown JK, et al. Cerebrospinal fluid myelin basic protein immunoreactivity as an indicator of brain damage in children. Dev Med Child Neurol 1985 Dec; 27 (6): 807-813
42. Noseworthy TW, Anderson BJ, Noseworthy AF, et al. Cerebrospinal fluid myelin basic protein as a prognostic marker in patients with head injury. Crit Care Med 1985 Sep; 13 (9): 743-746
43. Clapshaw PA, Muller HW, Wietholter H, et al. Simultaneousmeasurement of 20: 30 cyclic-nucleotide 30 phosphodiesterase and RNase activities in sera and spinal fluids of multiple sclerosis patients. J Neurochem 1984 Jan; 42 (1): 12-15 (Pubitemid 14216943)
44. Albert M, Antel J, Bruck W, et al. Extensive cortical remyelination in patients with chronic multiple sclerosis. Brain Pathol 2007 Apr; 17 (2): 129-138 (Pubitemid 46466131)
45. Bo L, Vedeler CA, Nyland HI, et al. Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J Neuropathol Exp Neurol 2003 Jul; 62 (7): 723-732 (Pubitemid 36870458)
46. Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005 Nov; 128 (Pt 11): 2705-2712 (Pubitemid 41552953)
47. Merkler D, Ernsting T, Kerschensteiner M, et al. A new focal EAE model of cortical demyelination: multiple sclerosis-like lesions with rapid resolution of inflammation and extensive remyelination. Brain 2006 Aug; 129 (Pt 8): 1972-1983 (Pubitemid 44289063)
48. Magliozzi R, Howell O, Vora A, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007 Apr; 130 (Pt 4): 1089-1104 (Pubitemid 47355604)
49. Magliozzi R, Columba-Cabezas S, Serafini B, et al. Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. J Neuroimmunol 2004 Mar; 148 (1-2): 11-23 (Pubitemid 38229554)
50. Serafini B, Rosicarelli B, Magliozzi R, et al. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 2004 Apr; 14 (2): 164-174 (Pubitemid 38656388)
51. Krumbholz M, Theil D, Cepok S, et al. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain 2006 Jan; 129 (Pt 1): 200-211 (Pubitemid 43063771)
52. Bartosik-Psujek H, Stelmasiak Z. Correlations between IL-4, IL-12 levels and CCL2, CCL5 levels in serum and cerebrospinal fluid of multiple sclerosis patients. J Neural Transm 2005 Jun; 112 (6): 797-803 (Pubitemid 40655571)
53. Drulovic J, Mostarica-Stojkovic M, Levic Z, et al. Interleukin-12 and tumor necrosis factor-alpha levels in cerebrospinal fluid of multiple sclerosis patients. J Neurol Sci 1997 Apr 15; 147 (2): 145-150 (Pubitemid 27132812)
54. Fassbender K, Ragoschke A, Rossol S, et al. Increased release of interleukin-12p40 in MS: association with intracerebral inflammation. Neurology 1998 Sep; 51 (3): 753-758 (Pubitemid 28449255)
55. Mahad DJ, Howell SJ, Woodroofe MN. Expression of chemokines in the CSF and correlation with clinical disease activity in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2002 Apr; 72 (4): 498-502 (Pubitemid 34289567)
56. Malmestrom C, Andersson BA, Haghighi S, et al. IL-6 and CCL2 levels in CSF are associated with the clinical course of MS: implications for their possible immunopathogenic roles. J Neuroimmunol 2006 Jun; 175 (1-2): 176-182 (Pubitemid 43765743)
57. Cannella B, Raine CS. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 1995 Apr; 37 (4): 424-435
58. Woodroofe MN, Cuzner ML. Cytokine mRNA expression in inflammatory multiple sclerosis lesions: detection by non-radioactive in situ hybridization. Cytokine 1993 Nov; 5 (6): 583-588
59. Frei K, Fredrikson S, Fontana A, et al. Interleukin-6 is elevated in plasma in multiple sclerosis. J Neuroimmunol 1991 Feb; 31 (2): 147-153
60. Maimone D, Gregory S, Arnason BG, et al. Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J Neuroimmunol 1991 Apr; 32 (1): 67-74
61. Padberg F, Feneberg W, Schmidt S, et al. CSF and serum levels of soluble interleukin-6 receptors (sIL-6R and sgp130), but not of interleukin-6 are altered in multiple sclerosis. J Neuroimmunol 1999 Oct 29; 99 (2): 218-223 (Pubitemid 29518234)
62. Stelmasiak Z, Koziol-Montewka M, Dobosz B, et al. IL-6 and sIL-6R concentration in the cerebrospinal fluid and serum of MS patients. Med Sci Monit 2001 Sep-Oct; 7 (5): 914-918 (Pubitemid 32928610)
63. Vladić A, Horvat G, Vukadin S, et al. Cerebrospinal fluid and serum protein levels of tumour necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and soluble interleukin-6 receptor (sIL-6R gp80) in multiple sclerosis patients. Cytokine 2002 Oct 21; 20 (2): 86-89
64. Michalopoulou M, Nikolaou C, Tavernarakis A, et al. Soluble interleukin-6 receptor (sIL-6R) in cerebrospinal fluid of patients with inflammatory and non inflammatory neurological diseases. Immunol Lett 2004 Jul 15; 94 (3): 183-189
65. Bagasra O, Michaels FH, Zheng YM, et al. Activation of the inducible form of nitric oxide synthase in the brains of patients with multiple sclerosis. Proc Natl Acad Sci U S A 1995 Dec 19; 92 (26): 12041-12045 (Pubitemid 26014007)
66. Bo L, Dawson TM, Wesselingh S, et al. Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Ann Neurol 1994 Nov; 36 (5): 778-786 (Pubitemid 24337639)
67. De Groot CJ, Ruuls SR, Theeuwes JW, et al. Immunocytochemical characterization of the expression of inducible and constitutive isoforms of nitric oxide synthase in demyelinating multiple sclerosis lesions. J Neuropathol Exp Neurol 1997 Jan; 56 (1): 10-20
68. Liu JS, Zhao ML, Brosnan CF, et al. Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions. Am J Pathol 2001 Jun; 158 (6): 2057-2066 (Pubitemid 32545191)
69. Oleszak EL, Zaczynska E, Bhattacharjee M, et al. Inducible nitric oxide synthase and nitrotyrosine are found in monocytes/macrophages and/or astrocytes in acute, but not in chronic, multiple sclerosis. Clin Diagn Lab Immunol 1998 Jul; 5 (4): 438-445 (Pubitemid 28342866)
70. Smith KJ, Lassmann H. The role of nitric oxide in multiple sclerosis. Lancet Neurol 2002 Aug; 1 (4): 232-241 (Pubitemid 37159185)
71. Thiel VE, Audus KL. Nitric oxide and blood-brain barrier integrity. Antioxid Redox Signal 2001 Apr; 3 (2): 273-278
72. Giovannoni G. Cerebrospinal fluid and serum nitric oxide metabolites in patients with multiple sclerosis. Mult Scler 1998 Feb; 4 (1): 27-30 (Pubitemid 28077433)
73. Brundin L, Morcos E, Olsson T, et al. Increased intrathecal nitric oxide formation in multiple sclerosis; cerebrospinal fluid nitrite as activity marker. Eur J Neurol 1999 Sep; 6 (5): 585-590 (Pubitemid 30028814)
74. Svenningsson A, Petersson AS, Andersen O, et al. Nitric oxide metabolites in CSF of patients with MS are related to clinical disease course. Neurology 1999 Nov 10; 53 (8): 1880-1882 (Pubitemid 29530375)
75. Yamashita T, Ando Y, Obayashi K, et al. Changes in nitrite and nitrate (NO2-/NO3-) levels in cerebrospinal fluid of patients with multiple sclerosis. J Neurol Sci 1997 Dec 9; 153 (1): 32-34
76. Acar G, Idiman F, Idiman E, et al. Nitric oxide as an activity marker in multiple sclerosis. J Neurol 2003 May; 250 (5): 588-592 (Pubitemid 36613303)
77. Rejdak K, Eikelenboom MJ, Petzold A, et al. CSF nitric oxidemetabolites are associated with activity and progression of multiple sclerosis. Neurology 2004 Oct 26; 63 (8): 1439-1445 (Pubitemid 39426278)
78. Calabrese V, Scapagnini G, Ravagna A, et al. Nitric oxide synthase is present in the cerebrospinal fluid of patients with active multiple sclerosis and is associated with increases in cerebrospinal fluid protein nitrotyrosine and S-nitrosothiols and with changes in glutathione levels. J Neurosci Res 2002 Nov 15; 70 (4): 580-587 (Pubitemid 35253528)
79. Chabas D, Baranzini SE, Mitchell D, et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 2001 Nov 23; 294 (5547): 1731-1735 (Pubitemid 33104847)
80. Sinclair C, Mirakhur M, Kirk J, et al. Up-regulation of osteopontin and alphaBeta-crystallin in the normal-appearing white matter of multiple sclerosis: an immunohistochemical study utilizing tissue microarrays. Neuropathol Appl Neurobiol 2005 Jun; 31 (3): 292-303 (Pubitemid 40769528)
81. Comabella M, Pericot I, Goertsches R, et al. Plasma osteopontin levels in multiple sclerosis. J Neuroimmunol 2005 Jan; 158 (1-2): 231-239 (Pubitemid 39626091)
82. Vogt MH, Lopatinskaya L, Smits M, et al. Elevated osteopontin levels in active relapsing-remitting multiple sclerosis. Ann Neurol 2003 Jun; 53 (6): 819-822 (Pubitemid 36622524)
83. Vogt MH, Floris S, Killestein J, et al. Osteopontin levels and increased disease activity in relapsing-remitting multiple sclerosis patients. J Neuroimmunol 2004 Oct; 155 (1-2): 155-160 (Pubitemid 39165788)
84. Chowdhury SA, Lin J, Sadiq SA. Specificity and correlation with disease activity of cerebrospinal fluid osteopontin levels in patients with multiple sclerosis. Arch Neurol 2008 Feb; 65 (2): 232-235 (Pubitemid 351240786)
85. Demetriou M, Binkert C, Sukhu B, et al. Fetuin/alpha2-HS glycoprotein is a transforming growth factor-beta type II receptor mimic and cytokine antagonist. J Biol Chem 1996 May 31; 271 (22): 12755-12761 (Pubitemid 26175845)
86. Dinzey J, Donelan N, Yan Q, et al. Elevated cerebrospinal fluid fetuin-A levels are a marker of disease activity in multiple sclerosis [abstract plus poster no. 335.8]. Neuroscience 2007; 2007 Nov 3-7; San Diego (CA) [online]. Available from URL: http://www.abstractsonline.com/viewer/ viewAbstractPrintFriendly.asp?CKey={9E32027B-3A56-4AA2-B59F-AA0F81A158AE} &SKey={9CC7E157-4CA9-4F70-AB5A-F5A395924942}&MKey={FF8B70E5-B7F9-4D07- A58A-C1068FDE9D25}&AKey={3A7DC0B9-D787-44AABD08-FA7BB2FE9004} [Accessed 2009 Aug 3]
87. Yan Q, Donelan N, Dinzey J, et al. Fetuin-A is a biomarker for disease activity and treatment efficacy in multiple sclerosis [abstract no. P897]. Mult Scler 2008; 14 (1 Suppl.): S292
88. Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 2008; 31: 247-269
89. Lim ET, Grant D, Pashenkov M, et al. Cerebrospinal fluid levels of brain specific proteins in optic neuritis. Mult Scler 2004 Jun; 10 (3): 261-265 (Pubitemid 38807451)
90. Miyazawa I, Nakashima I, Petzold A, et al. High CSF neurofilament heavy chain levels in neuromyelitis optica. Neurology 2007 Mar 13; 68 (11): 865-867 (Pubitemid 46568541)
91. Semra YK, Seidi OA, Sharief MK. Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability. J Neuroimmunol 2002 Jan; 122 (1-2): 132-139
92. Lycke JN, Karlsson JE, Andersen O, et al. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998 Mar; 64 (3): 402-404 (Pubitemid 28159853)
93. Malmestrom C, Haghighi S, Rosengren L, et al. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology 2003 Dec 23; 61 (12): 1720-1725 (Pubitemid 38020818)
94. Norgren N, Sundstrom P, Svenningsson A, et al. Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology 2004 Nov 9; 63 (9): 1586-1590 (Pubitemid 39507573)
95. Rejdak K, Petzold A, Stelmasiak Z, et al. Cerebrospinal fluid brain specific proteins in relation to nitric oxide metabolites during relapse of multiple sclerosis. Mult Scler 2008 Jan; 14 (1): 59-66 (Pubitemid 351541397)
96. Eikelenboom MJ, Petzold A, Lazeron RH, et al. Multiple sclerosis: neurofilament light chain antibodies are correlated to cerebral atrophy. Neurology 2003 Jan 28; 60 (2): 219-223 (Pubitemid 36152012)
97. Silber E, Semra YK, Gregson NA, et al. Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit. Neurology 2002 May 14; 58 (9): 1372-1381 (Pubitemid 34507164)
98. Bartos A, Fialova L, Soukupova J, et al. Antibodies against light neurofilaments in multiple sclerosis patients. Acta Neurol Scand 2007 Aug; 116 (2): 100-107 (Pubitemid 47174178)
99. Bartos A, Fialova L, Soukupova J, et al. Elevated intrathecal antibodies against the medium neurofilament subunit in multiple sclerosis. J Neurol 2007 Jan; 254 (1): 20-25 (Pubitemid 46295063)
100. Frankfort SV, Tulner LR, van Campen JP, et al. Amyloid beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: a review of recent literature. Curr Clin Pharmacol 2008 May; 3 (2): 123-131
101. Skinningsrud A, Stenset V, Gundersen AS, et al. Cerebrospinal fluid markers in Creutzfeldt-Jakob disease. Cerebrospinal Fluid Res 2008; 5: 14 [online]. Available from URL: http://www.cerebrospinalfluidresearch.com/content/ 5/1/14 [Accessed 2009 Aug 10]
102. Franz G, Beer R, Kampfl A, et al. Amyloid beta 1-42 and tau in cerebrospinal fluid after severe traumatic brain injury. Neurology 2003 May 13; 60 (9): 1457-1461 (Pubitemid 36554806)
103. Bartosik-Psujek H, Archelos JJ. Tau protein and 14-3-3 are elevated in the cerebrospinal fluid of patients with multiple sclerosis and correlate with intrathecal synthesis of IgG. J Neurol 2004 Apr; 251 (4): 414-420 (Pubitemid 38501298)
104. Bartosik-Psujek H, Stelmasiak Z. The CSF levels of total-tau and phosphotau in patients with relapsing-remitting multiple sclerosis. JNeural Transm 2006 Mar; 113 (3): 339-345 (Pubitemid 43201100)
105. Guimaraes I, Cardoso MI, Sa MJ. Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis. Mult Scler 2006 Jun; 12 (3): 354-356
106. Kapaki E, Paraskevas GP, Michalopoulou M, et al. Increased cerebrospinal fluid tau protein in multiple sclerosis. Eur Neurol 2000; 43 (4): 228-232 (Pubitemid 30258988)
107. Martinez-Yelamos A, Saiz A, Bas J, et al. Tau protein in cerebrospinal fluid: a possible marker of poor outcome in patients with early relapsing-remitting multiple sclerosis. Neurosci Lett 2004 Jun 3; 363 (1): 14-17 (Pubitemid 38639842)
108. Terzi M, Birinci A, Cetinkaya E, et al. Cerebrospinal fluid total tau protein levels in patients with multiple sclerosis. Acta Neurol Scand 2007 May; 115 (5): 325-330 (Pubitemid 46699430)
109. Jimenez-Jimenez FJ, Zurdo JM, Hernanz A, et al. Tau protein concentrations in cerebrospinal fluid of patients with multiple sclerosis. Acta Neurol Scand 2002 Dec; 106 (6): 351-354 (Pubitemid 36020742)
110. Brettschneider J, Maier M, Arda S, et al. Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis. Mult Scler 2005 Jun; 11 (3): 261-265 (Pubitemid 40775179)
111. Colucci M, Roccatagliata L, Capello E, et al. The 14-3-3 protein in multiple sclerosis: a marker of disease severity. Mult Scler 2004 Oct; 10 (5): 477-481 (Pubitemid 39207217)
112. Satoh J, Yukitake M, Kurohara K, et al. Detection of the 14-3-3 protein in the cerebrospinal fluid of Japanese multiple sclerosis patients presenting with severe myelitis. J Neurol Sci 2003 Aug 15; 212 (1-2): 11-20 (Pubitemid 36693961)
113. Martinez-Yelamos A, Rovira A, Sanchez-Valle R, et al. CSF 14-3-3 protein assay and MRI as prognostic markers in patients with a clinically isolated syndrome suggestive of MS. J Neurol 2004 Oct; 251 (10): 1278-1279 (Pubitemid 39517936)
114. Martinez-Yelamos A, Saiz A, Sanchez-Valle R, et al. 14-3-3 protein in the CSF as prognostic marker in early multiple sclerosis. Neurology 2001 Aug 28; 57 (4): 722-724 (Pubitemid 32783010)
115. Kawamoto Y, Akiguchi I, Kovacs GG, et al. Increased 14-3-3 immunoreactivity in glial elements in patients with multiple sclerosis. Acta Neuropathol 2004 Feb; 107 (2): 137-143 (Pubitemid 38159300)
116. Satoh J, Yamamura T, Arima K. The 14-3-3 protein epsilon isoform expressed in reactive astrocytes in demyelinating lesions of multiple sclerosis binds to vimentin and glial fibrillary acidic protein in cultured human astrocytes. Am J Pathol 2004 Aug; 165 (2): 577-592 (Pubitemid 38971387)
117. Alexander JS, Minagar A, Harper M, et al. Proteomic analysis of human cerebral endothelial cells activated by multiple sclerosis serum and IFNbeta-1b. J Mol Neurosci 2007; 32 (3): 169-178 (Pubitemid 47574965)
118. Chen MS, Huber AB, van der Haar ME, et al. Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1. Nature 2000 Jan 27; 403 (6768): 434-439
119. GrandPré T, Nakamura F, Vartanian T, et al. Identification of the Nogo inhibitor of axon regeneration as a Reticulon protein. Nature 2000 Jan 27; 403 (6768): 439-444 (Pubitemid 30073094)
120. Prinjha R, Moore SE, Vinson M, et al. Inhibitor of neurite outgrowth in humans. Nature 2000 Jan 27; 403 (6768): 383-384 (Pubitemid 30073077)
121. Buss A, Sellhaus B, Wolmsley A, et al. Expression pattern of NOGO-A protein in the human nervous system. Acta Neuropathol 2005 Aug; 110 (2): 113-119 (Pubitemid 41245199)
122. Kuhlmann T, Remington L, Maruschak B, et al. Nogo-A is a reliable oligodendroglial marker in adult human and mouse CNS and in demyelinated lesions. J Neuropathol Exp Neurol 2007 Mar; 66 (3): 238-246 (Pubitemid 46673279)
123. Jurewicz A, Matysiak M, Raine CS, et al. Soluble Nogo-A, an inhibitor of axonal regeneration, as a biomarker for multiple sclerosis. Neurology 2007 Jan 23; 68 (4): 283-287 (Pubitemid 46148340)
124. Lindsey JW, Crawford MP, Hatfield LM. Soluble Nogo-A in CSF is not a useful biomarker for multiple sclerosis. Neurology 2008 Jul 1; 71 (1): 35-37
125. Reindl M, Khantane S, Ehling R, et al. Serum and cerebrospinal fluid antibodies to Nogo-A in patients with multiple sclerosis and acute neurological disorders. J Neuroimmunol 2003 Dec; 145 (1-2): 139-147 (Pubitemid 37485975)
126. Onoue H, Satoh JI, Ogawa M, et al. Detection of anti-Nogo receptor autoantibody in the serum of multiple sclerosis and controls. Acta Neurol Scand 2007 Mar; 115 (3): 153-160 (Pubitemid 46219207)
127. Bjartmar C, Battistuta J, Terada N, et al. N-acetylaspartate is an axon-specific marker of mature white matter in vivo: a biochemical and immunohistochemical study on the rat optic nerve. Ann Neurol 2002 Jan; 51 (1): 51-58 (Pubitemid 34027977)
128. Bhakoo KK, Pearce D. In vitro expression of N-acetyl aspartate by oligodendrocytes: implications for proton magnetic resonance spectroscopy signal in vivo. J Neurochem 2000 Jan; 74 (1): 254-262
129. Bjartmar C, Kidd G, Mork S, et al. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol 2000 Dec; 48 (6): 893-901
130. Davie CA, Hawkins CP, Barker GJ, et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 1994 Feb; 117 (Pt 1): 49-58 (Pubitemid 24103384)
131. De Stefano N, Guidi L, Stromillo ML, et al. Imaging neuronal and axonal degeneration in multiple sclerosis. Neurol Sci 2003 Dec; 24 Suppl. 5: S283-6 (Pubitemid 37493202)
132. De Stefano N, Iannucci G, Sormani MP, et al. MR correlates of cerebral atrophy in patients with multiple sclerosis. J Neurol 2002 Aug; 249 (8): 1072-1077 (Pubitemid 35002232)
133. De Stefano N, Matthews PM, Fu L, et al. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis: results of a longitudinal magnetic resonance spectroscopy study. Brain 1998 Aug; 121 (Pt 8): 1469-1477 (Pubitemid 28349900)
134. Rovaris M, Gambini A, Gallo A, et al. Axonal injury in early multiple sclerosis is irreversible and independent of the short-term disease evolution. Neurology 2005 Nov 22; 65 (10): 1626-1630 (Pubitemid 41689479)
135. Jasperse B, Jakobs C, Eikelenboom MJ, et al. N-acetylaspartic acid in cerebrospinal fluid of multiple sclerosis patients determined by gas-chromatography-mass spectrometry. J Neurol 2007 May; 254 (5): 631-637 (Pubitemid 46781977)
136. Rigotti DJ, Inglese M, Gonen O. Whole-brain N-acetylaspartate as a surrogate marker of neuronal damage in diffuse neurologic disorders. AJNR Am J Neuroradiol 2007 Nov-Dec; 28 (10): 1843-1849 (Pubitemid 350176510)
137. Ghaffar O, Feinstein A. The neuropsychiatry of multiple sclerosis: a review of recent developments. Curr Opin Psychiatry 2007 May; 20 (3): 278-285 (Pubitemid 46588302)
138. Selby MJ, Ling N, Williams JM, et al. Interferon beta 1-b in verbal memory functioning of patients with relapsing-remitting multiple sclerosis. Percept Mot Skills 1998 Jun; 86 (3 Pt 1): 1099-1106 (Pubitemid 128700892)
139. Weinstein A, Schwid SR, Schiffer RB, et al. Neuropsychologic status in multiple sclerosis after treatment with glatiramer. Arch Neurol 1999 Mar; 56 (3): 319-324 (Pubitemid 29120229)
140. Roses AD. Apolipoprotein E alleles as risk factors in Alzheimer's disease. Annu Rev Med 1996; 47: 387-400 (Pubitemid 26138899)
141. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 1993 Mar 1; 90 (5): 1977-1981 (Pubitemid 23069980)
142. Fazekas F, Enzinger C, Ropele S, et al. The impact of our genes: consequences of the apolipoprotein E polymorphism in Alzheimer disease and multiple sclerosis. J Neurol Sci 2006 Jun 15; 245 (1-2): 35-39 (Pubitemid 43775934)
143. De Stefano N, Bartolozzi ML, Nacmias B, et al. Influence of apolipoprotein E epsilon4 genotype on brain tissue integrity in relapsing-remitting multiple sclerosis. Arch Neurol 2004 Apr; 61 (4): 536-540 (Pubitemid 38923743)
144. Enzinger C, Ropele S, Smith S, et al. Accelerated evolution of brain atrophy and "black holes" in MS patients with APOE-epsilon 4. Ann Neurol 2004 Apr; 55 (4): 563-569
145. Enzinger C, Ropele S, Strasser-Fuchs S, et al. Lower levels of N-acetylaspartate in multiple sclerosis patients with the apolipoprotein E epsilon4 allele. Arch Neurol 2003 Jan; 60 (1): 65-70 (Pubitemid 36078110)
146. Zakrzewska-Pniewska B, Styczynska M, Podlecka A, et al. Association of apolipoprotein E and myeloperoxidase genotypes to clinical course of familial and sporadic multiple sclerosis. Mult Scler 2004 Jun; 10 (3): 266-271 (Pubitemid 38807452)
147. Zwemmer JN, van Veen T, van Winsen L, et al. No major association of ApoE genotype with disease characteristics and MRI findings in multiple sclerosis. Mult Scler 2004 Jun; 10 (3): 272-277
148. Shi J, Zhao CB, Vollmer TL, et al. APOE epsilon 4 allele is associated with cognitive impairment in patients with multiple sclerosis. Neurology 2008 Jan 15; 70 (3): 185-190
149. Koutsis G, Panas M, Karadima G, et al. APOE genotypes in Greek multiple sclerosis patients: no effect on the MS Severity Score. J Neurol 2007 Mar; 254 (3): 394-395
150. Savettieri G, Messina D, Andreoli V, et al. Gender-related effect of clinical and genetic variables on the cognitive impairment in multiple sclerosis. J Neurol 2004 Oct; 251 (10): 1208-1214 (Pubitemid 39517923)
151. Ewers M, Zhong Z, Burger K, et al. Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease. Brain 2008 May; 131 (Pt 5): 1252-1258
152. Marksteiner J, Hinterhuber H, Humpel C. Cerebrospinal fluid biomarkers for diagnosis of Alzheimer's disease: beta-amyloid (1-42), tau, phospho-tau-181 and total protein. Drugs Today (Barc) 2007 Jun; 43 (6): 423-431
153. Vidal R, Frangione B, Rostagno A, et al. A stop-codon mutation in the BRI gene associated with familial British dementia. Nature 1999 Jun 24; 399 (6738): 776-781 (Pubitemid 29293172)
154. Mattsson N, Axelsson M, Haghighi S, et al. Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis. Mult Scler 2009 Apr; 15: 448-454
155. Fotinopoulou A, Tsachaki M, Vlavaki M, et al. BRI2 interacts with amyloid precursor protein (APP) and regulates amyloid beta (Abeta) production. J Biol Chem 2005 Sep 2; 280 (35): 30768-30772 (Pubitemid 41291806)
156. Kim J, Miller VM, Levites Y, et al. BRI2 (ITM2b) inhibits Abeta deposition in vivo. J Neurosci 2008 Jun 4; 28 (23): 6030-6036
157. Matsuda S, Giliberto L, Matsuda Y, et al. The familial dementia BRI2 gene binds the Alzheimer gene amyloid-beta precursor protein and inhibits amyloid-beta production. J Biol Chem 2005 Aug 12; 280 (32): 28912-28916 (Pubitemid 41161336)
158. Harris VK, Wang G, Diamanduros AW, et al. Bri-CT amyloid peptide levels are decreased in the cerebrospinal fluid of progressive multiple sclerosis patients [abstract]. Neurology 2006 Mar 14; 66 (5 Suppl. 2): A370-1
159. Good PI, O'Hara NB, Chhua N, et al. Cognition and cerebellar dysfunction in multiple sclerosis are associated with decreased Bri2 expression [abstract]. Neurology 2008 Mar 11; 70 (11 Suppl. 1): A412
160. Sadiq SA, Revesz K, Lassman A, et al. Antibodies to interferon-beta in patients with multiple sclerosis: detection and clinical effects. Neurology 1996; 46 Suppl. 2: A136
161. Bendtzen K. Anti-IFN BAb and NAb antibodies: a minireview. Neurology 2003 Nov 11; 61 (9 Suppl. 5): S6-10
162. Boz C, Oger J, Gibbs E, et al. Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study. Mult Scler 2007 Nov; 13 (9): 1127-1137 (Pubitemid 351541416)
163. Prince HE, Lape-Nixon M, Audette C, et al. Identification of interferon-beta antibodies in a reference laboratory setting: findings for 1144 consecutive sera. J Neuroimmunol 2007 Oct; 190 (1-2): 165-169 (Pubitemid 47625613)
164. Pachner AR, Oger J, Palace J. The measurement of antibodies binding to IFNbeta in MS patients treated with IFNbeta. Neurology 2003 Nov 11; 61 (9 Suppl. 5): S18-20 (Pubitemid 37386114)
165. Goodin DS, Frohman EM, Hurwitz B, et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2007 Mar 27; 68 (13): 977-984 (Pubitemid 46569129)
166. Pachner AR, Dail D, Pak E, et al. The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies. J Neuroimmunol 2005 Sep; 166 (1-2): 180-188 (Pubitemid 41078773)
167. Calabresi PA, Giovannoni G, Confavreux C, et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 2007 Oct 2; 69 (14): 1391-1403 (Pubitemid 47511460)
168. Brenner T, Arnon R, Sela M, et al. Humoral and cellular immune responses to copolymer 1 in multiple sclerosis patients treated with copaxone. J Neuroimmunol 2001 Apr 2; 115 (1-2): 152-160 (Pubitemid 32245663)
169. Salama HH, Hong J, Zang YC, et al. Blocking effects of serum reactive antibodies induced by glatiramer acetate treatment in multiple sclerosis. Brain 2003 Dec; 126 (Pt 12): 2638-2647 (Pubitemid 37463083)
170. Teitelbaum D, Brenner T, Abramsky O, et al. Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy. Mult Scler 2003 Dec; 9 (6): 592-599 (Pubitemid 37479408)
171. Bertolotto A, Gilli F, Sala A, et al. Evaluation of bioavailability of three types of IFNbeta in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification. J Immunol Methods 2001 Oct 1; 256 (1-2): 141-152 (Pubitemid 32769923)
172. Gilli F, Marnetto F, Caldano M, et al. Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis. J Neuroimmunol 2005 Jan; 158 (1-2): 195-203 (Pubitemid 39626087)
173. Pachner A, Narayan K, Price N, et al. MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity. Mol Diagn 2003; 7 (1): 17-25 (Pubitemid 37339029)
174. Bertolotto A, Gilli F, Sala A, et al. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology 2003 Feb 25; 60 (4): 634-639 (Pubitemid 36246082)
175. Deisenhammer F, Reindl M, Harvey J, et al. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 1999 Apr 12; 52 (6): 1239-1243 (Pubitemid 29177928)
176. Gilli F, Bertolotto A, Sala A, et al. Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs. Brain 2004 Feb; 127 (Pt 2): 259-268 (Pubitemid 38160311)
177. Malucchi S, Gilli F, Caldano M, et al. Predictive markers for response to interferon therapy in patients with multiple sclerosis. Neurology 2008 Mar 25; 70 (13 Pt 2): 1119-1127
178. Gilli F, Marnetto F, Caldano M, et al. Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1. Mult Scler 2006 Feb; 12 (1): 47-57
179. Santos R, Weinstock-Guttman B, Tamano-Blanco M, et al. Dynamics of interferon-beta modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-beta neutralizing antibodies. J Neuroimmunol 2006 Jul; 176 (1-2): 125-133 (Pubitemid 44080329)
180. Wandinger KP, Lunemann JD, Wengert O, et al. TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. Lancet 2003 Jun 14; 361 (9374): 2036-2043
181. Lunemann JD, Waiczies S, Ehrlich S, et al. Death ligand TRAIL induces no apoptosis but inhibits activation of human (auto)antigen-specific T cells. J Immunol 2002 May 15; 168 (10): 4881-4888 (Pubitemid 34495949)
182. Aktas O, Schulze-Topphoff U, Zipp F. The role of TRAIL/TRAIL receptors in central nervous system pathology. Front Biosci 2007; 12: 2912-2921
183. Aktas O, Smorodchenko A, Brocke S, et al. Neuronal damage in autoimmune neuroinflammationmediated by the death ligand TRAIL. Neuron 2005 May 5; 46 (3): 421-432 (Pubitemid 40616886)
184. Buttmann M, Merzyn C, Hofstetter HH, et al. TRAIL, CXCL10 and CCL2 plasma levels during long-term interferon-beta treatment of patients with multiple sclerosis correlate with flu-like adverse effects but do not predict therapeutic response. J Neuroimmunol 2007 Oct; 190 (1-2): 170-176 (Pubitemid 47625614)
185. Lau AS, Hannigan GE, Freedman MH, et al. Regulation of interferon receptor expression in human blood lymphocytes in vitro and during interferon therapy. J Clin Invest 1986 May; 77 (5): 1632-1638 (Pubitemid 16047109)
186. Oliver B, Mayorga C, Fernandez V, et al. Interferon receptor expression in multiple sclerosis patients. J Neuroimmunol 2007 Feb; 183 (1-2): 225-231 (Pubitemid 46204911)
187. Gilli F, Valentino P, Caldano M, et al. Expression and regulation of IFNalpha/beta receptor in IFNbeta-treated patients with multiple sclerosis. Neurology 2008 Dec 9; 71 (24): 1940-1947
188. Dumont D, Noben JP, Raus J, et al. Proteomic analysis of cerebrospinal fluid from multiple sclerosis patients. Proteomics 2004 Jul; 4 (7): 2117-2124 (Pubitemid 38880377)
189. Hammack BN, Fung KY, Hunsucker SW, et al. Proteomic analysis of multiple sclerosis cerebrospinal fluid. Mult Scler 2004 Jun; 10 (3): 245-260 (Pubitemid 38807450)
190. Lehmensiek V, Sussmuth SD, Tauscher G, et al. Cerebrospinal fluid proteome profile in multiple sclerosis. Mult Scler 2007 Aug; 13 (7): 840-849 (Pubitemid 351540854)
191. Noben JP, Dumont D, Kwasnikowska N, et al. Lumbar cerebrospinal fluid proteome in multiple sclerosis: characterization by ultrafiltration, liquid chromatography, and mass spectrometry. J Proteome Res 2006 Jul; 5 (7): 1647-1657 (Pubitemid 44036138)
192. Irani DN, Anderson C, Gundry R, et al. Cleavage of cystatin C in the cerebrospinal fluid of patients with multiple sclerosis. Ann Neurol 2006 Feb; 59 (2): 237-247 (Pubitemid 43202476)
193. Stoevring B, Jaliashvili I, Thougaard AV, et al. Tetranectin in cerebrospinal fluid of patients with multiple sclerosis. Scand J Clin Lab Invest 2006; 66 (7): 577-583 (Pubitemid 44764391)
194. Nakashima I, Fujinoki M, Fujihara K, et al. Alteration of cystatin C in the cerebrospinal fluid of multiple sclerosis. Ann Neurol 2007 Aug; 62 (2): 197-200 (Pubitemid 47546506)
195. Del Boccio P, Pieragostino D, Lugaresi A, et al. Cleavage of cystatin C is not associated with multiple sclerosis. Ann Neurol 2007 Aug; 62 (2): 201-224 (Pubitemid 47546507)
196. Hansson SF, Simonsen AH, Zetterberg H, et al. Cystatin C in cerebrospinal fluid and multiple sclerosis. Ann Neurol 2007 Aug; 62 (2): 193-216 (Pubitemid 47546505)
197. Iwanami A, Kaneko S, Nakamura M, et al. Transplantation of human neural stem cells for spinal cord injury in primates. J Neurosci Res 2005 Apr 15; 80 (2): 182-190 (Pubitemid 40676302)
198. Ousman SS, Tomooka BH, van Noort JM, et al. Protective and therapeutic role for alphaB-crystallin in autoimmune demyelination. Nature 2007 Jul 26; 448 (7152): 474-479
199. Agius MA, Kirvan CA, Schafer AL, et al. High prevalence of anti-alpha-crystallin antibodies in multiple sclerosis: correlation with severity and activity of disease. Acta Neurol Scand 1999 Sep; 100 (3): 139-147
200. Celet B, Akman-Demir G, Serdaroglu P, et al. Anti-alpha B-crystallin immunoreactivity in inflammatory nervous system diseases. J Neurol 2000 Dec; 247 (12): 935-939 (Pubitemid 32042660)
201. Vojdani A, Vojdani E, Cooper E. Antibodies to myelin basic protein, myelin oligodendrocytes peptides, alpha-beta-crystallin, lymphocyte activation and cytokine production in patients with multiple sclerosis. J Intern Med 2003 Oct; 254 (4): 363-374 (Pubitemid 37211260)
202. Han MH, Hwang SI, Roy DB, et al. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 2008 Feb 28; 451 (7182): 1076-1081
203. Quintana FJ, Farez MF, Viglietta V, et al. Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc Natl Acad Sci U S A 2008 Dec 2; 105 (48): 18889-18894